Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i>
The inadequate eradication of pulmonary infections and chronic inflammation are significant complications in cystic fibrosis (CF) patients, who usually suffer from persistent and frequent lung infections caused by several pathogens, particularly <i>Pseudomonas aeruginosa</i> (<i>P....
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/5/960 |
| _version_ | 1797496749662666752 |
|---|---|
| author | Nouf M. Alzahrani Rayan Y. Booq Ahmad M. Aldossary Abrar A. Bakr Fahad A. Almughem Ahmed J. Alfahad Wijdan K. Alsharif Somayah J. Jarallah Waleed S. Alharbi Samar A. Alsudir Essam J. Alyamani Essam A. Tawfik Abdullah A. Alshehri |
| author_facet | Nouf M. Alzahrani Rayan Y. Booq Ahmad M. Aldossary Abrar A. Bakr Fahad A. Almughem Ahmed J. Alfahad Wijdan K. Alsharif Somayah J. Jarallah Waleed S. Alharbi Samar A. Alsudir Essam J. Alyamani Essam A. Tawfik Abdullah A. Alshehri |
| author_sort | Nouf M. Alzahrani |
| collection | DOAJ |
| description | The inadequate eradication of pulmonary infections and chronic inflammation are significant complications in cystic fibrosis (CF) patients, who usually suffer from persistent and frequent lung infections caused by several pathogens, particularly <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>). The ability of pathogenic microbes to protect themselves from biofilms leads to the development of an innate immune response and antibiotic resistance. In the present work, a reference bacterial strain of <i>P. aeruginosa</i> (PA01) and a multidrug-resistant isolate (MDR 7067) were used to explore the microbial susceptibility to three antibiotics (ceftazidime, imipenem, and tobramycin) and an anti-biofilm peptide (IDR-1018 peptide) using the minimum inhibition concentration (MIC). The most effective antibiotic was then encapsulated into liposomal nanoparticles and the IDR-1018 peptide with antibacterial activity, and the ability to disrupt the produced biofilm against PA01 and MDR 7067 was assessed. The MIC evaluation of the tobramycin antibacterial activity showed an insignificant effect on the liposomes loaded with tobramycin and liposomes encapsulating tobramycin and IDR-1018 against both <i>P. aeruginosa</i> strains to free tobramycin. Nevertheless, the biofilm formation was significantly reduced (<i>p</i> < 0.05) at concentrations of ≥4 μg/mL and ≤32 μg/mL for PA01 and ≤32 μg/mL for MDR 7067 when loading tobramycin into liposomes, with or without the anti-biofilm peptide compared to the free antibiotic, empty liposomes, and IDR-1018-loaded liposomes. A tobramycin concentration of ≤256 µg/mL was safe when exposed to a lung carcinoma cell line upon its encapsulation into the liposomal formulation. Tobramycin-loaded liposomes could be a potential candidate for treating lung-infected animal models owing to the high therapeutic efficacy and safety profile of this system compared to the free administration of the antibiotic. |
| first_indexed | 2024-03-10T03:08:02Z |
| format | Article |
| id | doaj.art-e9a244fb22964479ab915f78f1a88e23 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T03:08:02Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-e9a244fb22964479ab915f78f1a88e232023-11-23T12:37:15ZengMDPI AGPharmaceutics1999-49232022-04-0114596010.3390/pharmaceutics14050960Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i>Nouf M. Alzahrani0Rayan Y. Booq1Ahmad M. Aldossary2Abrar A. Bakr3Fahad A. Almughem4Ahmed J. Alfahad5Wijdan K. Alsharif6Somayah J. Jarallah7Waleed S. Alharbi8Samar A. Alsudir9Essam J. Alyamani10Essam A. Tawfik11Abdullah A. Alshehri12National Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi ArabiaThe inadequate eradication of pulmonary infections and chronic inflammation are significant complications in cystic fibrosis (CF) patients, who usually suffer from persistent and frequent lung infections caused by several pathogens, particularly <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>). The ability of pathogenic microbes to protect themselves from biofilms leads to the development of an innate immune response and antibiotic resistance. In the present work, a reference bacterial strain of <i>P. aeruginosa</i> (PA01) and a multidrug-resistant isolate (MDR 7067) were used to explore the microbial susceptibility to three antibiotics (ceftazidime, imipenem, and tobramycin) and an anti-biofilm peptide (IDR-1018 peptide) using the minimum inhibition concentration (MIC). The most effective antibiotic was then encapsulated into liposomal nanoparticles and the IDR-1018 peptide with antibacterial activity, and the ability to disrupt the produced biofilm against PA01 and MDR 7067 was assessed. The MIC evaluation of the tobramycin antibacterial activity showed an insignificant effect on the liposomes loaded with tobramycin and liposomes encapsulating tobramycin and IDR-1018 against both <i>P. aeruginosa</i> strains to free tobramycin. Nevertheless, the biofilm formation was significantly reduced (<i>p</i> < 0.05) at concentrations of ≥4 μg/mL and ≤32 μg/mL for PA01 and ≤32 μg/mL for MDR 7067 when loading tobramycin into liposomes, with or without the anti-biofilm peptide compared to the free antibiotic, empty liposomes, and IDR-1018-loaded liposomes. A tobramycin concentration of ≤256 µg/mL was safe when exposed to a lung carcinoma cell line upon its encapsulation into the liposomal formulation. Tobramycin-loaded liposomes could be a potential candidate for treating lung-infected animal models owing to the high therapeutic efficacy and safety profile of this system compared to the free administration of the antibiotic.https://www.mdpi.com/1999-4923/14/5/960cystic fibrosisliposomestobramycininnate defense regulator peptide-1018 (IDR-1018)biofilm<i>Pseudomonas aeruginosa</i> |
| spellingShingle | Nouf M. Alzahrani Rayan Y. Booq Ahmad M. Aldossary Abrar A. Bakr Fahad A. Almughem Ahmed J. Alfahad Wijdan K. Alsharif Somayah J. Jarallah Waleed S. Alharbi Samar A. Alsudir Essam J. Alyamani Essam A. Tawfik Abdullah A. Alshehri Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> Pharmaceutics cystic fibrosis liposomes tobramycin innate defense regulator peptide-1018 (IDR-1018) biofilm <i>Pseudomonas aeruginosa</i> |
| title | Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> |
| title_full | Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> |
| title_fullStr | Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> |
| title_full_unstemmed | Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> |
| title_short | Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> |
| title_sort | liposome encapsulated tobramycin and idr 1018 peptide mediated biofilm disruption and enhanced antimicrobial activity against i pseudomonas aeruginosa i |
| topic | cystic fibrosis liposomes tobramycin innate defense regulator peptide-1018 (IDR-1018) biofilm <i>Pseudomonas aeruginosa</i> |
| url | https://www.mdpi.com/1999-4923/14/5/960 |
| work_keys_str_mv | AT noufmalzahrani liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT rayanybooq liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT ahmadmaldossary liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT abrarabakr liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT fahadaalmughem liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT ahmedjalfahad liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT wijdankalsharif liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT somayahjjarallah liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT waleedsalharbi liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT samaraalsudir liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT essamjalyamani liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT essamatawfik liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai AT abdullahaalshehri liposomeencapsulatedtobramycinandidr1018peptidemediatedbiofilmdisruptionandenhancedantimicrobialactivityagainstipseudomonasaeruginosai |